| Literature DB >> 25886492 |
Carlene J Wilson1,2, Ingrid Hk Flight3,4,5, Deborah Turnbull6, Tess Gregory7,8, Stephen R Cole3, Graeme P Young3, Ian T Zajac5.
Abstract
BACKGROUND: In Australia, bowel cancer screening participation using faecal occult blood testing (FOBT) is low. Decision support tailored to psychological predictors of participation may increase screening. The study compared tailored computerised decision support to non-tailored computer or paper information. The primary outcome was FOBT return within 12 weeks. Additional analyses were conducted on movement in decision to screen and change on psychological variables.Entities:
Mesh:
Year: 2015 PMID: 25886492 PMCID: PMC4403749 DOI: 10.1186/s12911-015-0147-5
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Study interventions by phase and arm
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
| |||
| Introductory letter Information sheet Eligibility Questionnaire (EQ) Pre-paid envelope | Group 1. Internet-based Tailored material (TPDS) | Information sheet; Baseline survey completed online (BS); Receipt of tailored messages; Electronic version of NBCSP consumer information booklet | FOBT kit mailed to those who completed BS; Reminder to revisit online tailored messages and NBCSP consumer information booklet | Endpoint Survey (ES) Completed Online | Telephone Interview (subset)b |
|
| Group 2. Internet-based non-tailored material (NTPDS) | Information sheet; Baseline survey completed; online Electronic version of NBCSP consumer information booklet | FOBT kit mailed to those who completed BS; Reminder to revisit online NBCSP consumer information booklet | Endpoint Survey completed online | Telephone Interview (subset)b |
| Those returning EQ and meeting eligibility criteria randomised to 1 of 3 groups | Group 3. Paper-based non-tailored material (usual practice control group, CG) | Information sheet; Baseline survey completed on paper and returned to the researchers | FOBT kit mailed to those who completed BS; Printed version of NBCSP consumer information booklet | Endpoint survey completed on paper and returned | Telephone Interview (subset)b |
aAdapted from Wilson et al. [25].
bThese results published [33].
Figure 1CONSORT flow diagram . *The intention-to-treat analyses included all eligible participants who responded to the Eligibility Questionnaire and were randomised to a group regardless of further participation. In the Per Protocol analyses, we only included participants who completed a baseline survey and were mailed an FOBT. The PHM variable change sample constituted participants who completed an endpoint survey and contributed to analyses of change in baseline PHM variable scores following exposure to group allocation. a N = 63 participants, representing the 3 study arms and consisting of those who had both returned and not returned an FOBT, continued to a qualitative phase [33].
PHM, self-efficacy and faecal aversion variables; PAPM decision stages
|
| |
|---|---|
|
| |
|
|
|
|
| |
| Salience and Coherence | Having colorectal cancer screening is an important thing for me to dob |
| Colorectal cancer screening makes sense to me | |
| Having colorectal cancer screening can help to protect my health | |
| I will be just as healthy if I avoid having colorectal cancer screeningc | |
| Social Influence | Members of my immediate family think I should have colorectal cancer screeningb |
| I want to do what members of my immediate family think I should do about colorectal cancer screening | |
| My doctor or health professional thinks I should have colorectal cancer screening | |
| I want to do what my doctor or health professional thinks I should do about colorectal cancer screening | |
| Cancer Worries | I am afraid of having an abnormal colorectal cancer screening test result |
| I am worried that colorectal cancer screening will show that I have colorectal cancer | |
| Perceived Susceptibility | Compared with other persons my age, I am at lower risk for colorectal cancerc |
| The chance that I might develop colorectal cancer is high | |
| The chances that I will develop colorectal polyps are highb | |
| Response Efficacy | When colorectal polyps are found and removed, colorectal cancer can be preventedb |
| When colorectal cancer is found early, it can be cured | |
| Self-efficacy | I think that doing the test would be easy for meb |
| Finding time to do the test would be difficult for mec | |
| Completing the test correctly would be easy for me | |
| Faecal Aversion | Collecting faeces for the purpose of bowel cancer screening is distastefulb,c |
| Collecting faeces for the purpose of bowel cancer screening is unhygienicc | |
| Giving a sample of faeces to another person is embarrassingc | |
aPreventive Health Model (PHM) items reproduced from Tiro et al. [35].
bStatements used for tailored assessment.
cItems were reverse coded.
Demographic characteristics of ITT and per protocol samples
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||
| ITT Sample | AGE | 50–54 | 348 | 30.7% | 330 | 29.0% | 331 | 29.1% |
| 55–59 | 302 | 26.6% | 298 | 26.2% | 315 | 27.7% | ||
| 60–64 | 266 | 23.4% | 296 | 26.1% | 275 | 24.2% | ||
| 65–69 | 126 | 11.1% | 123 | 10.8% | 142 | 12.5% | ||
| 70–74 | 93 | 8.2% | 89 | 7.8% | 74 | 6.5% | ||
| SEX | Male | 557 | 49.1% | 556 | 48.9% | 559 | 49.2% | |
| Female | 578 | 50.9% | 580 | 51.1% | 578 | 50.8% | ||
| SEIFA* | SEI_AD <5 | 173 | 15.2% | 173 | 15.2% | 190 | 16.7% | |
| SEI_AD >5 | 962 | 84.8% | 963 | 84.8% | 947 | 83.3% | ||
| STATE | NSW | 219 | 19.3% | 220 | 19.4% | 220 | 19.3% | |
| QLD | 214 | 18.9% | 214 | 18.8% | 215 | 18.9% | ||
| SA | 242 | 21.3% | 242 | 21.3% | 241 | 21.2% | ||
| VIC | 210 | 18.5% | 209 | 18.4% | 210 | 18.5% | ||
| WA | 250 | 22.0% | 251 | 22.1% | 251 | 22.1% | ||
| Per Protocol Sample | AGE | 50–54 | 238 | 28.9% | 207 | 28.9% | 205 | 28.0% |
| 55–59 | 220 | 26.7% | 187 | 26.1% | 200 | 27.4% | ||
| 60–64 | 195 | 23.7% | 177 | 24.7% | 184 | 25.2% | ||
| 65–69 | 100 | 12.2% | 85 | 11.9% | 90 | 12.3% | ||
| 70–74 | 70 | 8.5% | 60 | 8.4% | 52 | 7.1% | ||
| SEX | Male | 413 | 50.2% | 368 | 51.4% | 371 | 50.8% | |
| Female | 410 | 49.8% | 348 | 48.6% | 360 | 49.2% | ||
| SEIFA* | SEI_AD <5 | 128 | 15.6% | 97 | 13.5% | 111 | 15.2% | |
| SEI_AD >5 | 695 | 84.4% | 619 | 86.5% | 620 | 84.8% | ||
| STATE | NSW | 154 | 18.7% | 128 | 17.9% | 123 | 16.8% | |
| QLD | 162 | 19.7% | 148 | 20.7% | 139 | 19.0% | ||
| SA | 178 | 21.6% | 151 | 21.1% | 162 | 22.2% | ||
| VIC | 151 | 18.3% | 129 | 18.0% | 128 | 17.5% | ||
| WA | 178 | 21.6% | 160 | 22.3% | 179 | 24.5% | ||
*SEIFA: <5 = higher disadvantage and lower advantage; >5 = lower disadvantage and higher advantage.
Multivariate GLM of predictors of FOBT return utilising the ITT sample (N = 3,408)
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
| ||||
| Control | Tailored | 0.87 | 0.11 | 0.74 | 1.03 |
| Non-tailored | 0.90 | 0.22 | 0.76 | 1.06 | |
| Female | Male | 1.05 | 0.51 | 0.91 | 1.20 |
| SEIFA - LOWER | SEIFA - HIGHER | 1.16 | 0.14 | 0.95 | 1.41 |
| Age 50–54 years | 55-59 | 1.29 | 0.01 | 1.08 | 1.54 |
| 60-64 | 1.67 | 0.00 | 1.39 | 2.01 | |
| 65-69 | 1.75 | 0.00 | 1.38 | 2.22 | |
| 70-74 | 1.97 | 0.00 | 1.49 | 2.62 | |
| WA | NSW | 0.73 | 0.00 | 0.59 | 0.90 |
| QLD | 1.13 | 0.25 | 0.92 | 1.40 | |
| SA | 1.19 | 0.11 | 0.96 | 1.48 | |
| VIC | 0.84 | 0.11 | 0.68 | 1.04 | |
Multivariate GLM of predictors of FOBT return utilizing the per protocol sample (N = 2,270)
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
| ||||
| Control | Tailored | 1.36 | 0.01 | 1.07 | 1.74 |
| Non-tailored | 1.69 | 0.00 | 1.31 | 2.18 | |
| Female | Male | 0.81 | 0.04 | 0.65 | 0.99 |
| SEIFA - LOWER | SEIFA - HIGHER | 0.94 | 0.71 | 0.69 | 1.29 |
| Age 50–54 years | 55-59 | 1.53 | 0.00 | 1.19 | 1.98 |
| 60-64 | 3.06 | 0.00 | 2.26 | 4.14 | |
| 65-69 | 2.22 | 0.00 | 1.55 | 3.18 | |
| 70-74 | 3.07 | 0.00 | 1.93 | 4.88 | |
| WA | NSW | 0.81 | 0.20 | 0.60 | 1.11 |
| QLD | 1.18 | 0.32 | 0.85 | 1.63 | |
| SA | 1.38 | 0.06 | 0.99 | 1.93 | |
| VIC | 0.86 | 0.35 | 0.63 | 1.18 | |
Descriptive statistics for baseline psychosocial variables in the Per Protocol Sample (N = 2,270)
|
|
|
|
| ||
|---|---|---|---|---|---|
| Salience & Coherence | Mean | 4.31 | 4.29 | 4.24 | 4.28 |
| SD | 0.53 | 0.57 | 0.55 | 0.55 | |
| Cancer Worries | Mean | 2.80 | 2.90 | 2.85 | 2.85 |
|
| 1.02 | 0.98 | 1.00 | 1.00 | |
| Perceived Susceptibility | Mean | 2.80 | 2.89 | 2.82 | 2.83 |
| SD | 0.54 | 0.57 | 0.53 | 0.55 | |
| Response Efficacy | Mean | 3.72 | 3.78 | 3.74 | 3.75 |
| SD | 0.59 | 0.53 | 0.55 | 0.56 | |
| Self-Efficacy | Mean | 3.96 | 3.97 | 3.96 | 3.96 |
| SD | 0.62 | 0.55 | 0.55 | 0.57 | |
| Faecal Aversion | Mean | 2.43 | 2.45 | 2.46 | 2.45 |
| SD | 0.86 | 0.84 | 0.81 | 0.84 | |
| Social Influence | Mean | 3.48 | 3.68 | 3.63 | 3.59 |
| SD | 0.75 | 0.68 | 0.66 | 0.70 |
Note: Correlations between variables were low, demonstrating relative independence: Mean r =0.11, Min r =0.01, Max r =0.30.
Multivariate GLM of predictors of FOBT return for per protocol sample (N = 2,270) including significant psychosocial variables
|
|
|
|
|
| |
|---|---|---|---|---|---|
|
|
| ||||
| Control | Tailored | 1.37 | 0.01 | 1.07 | 1.76 |
| Non-tailored | 1.68 | 0.00 | 1.30 | 2.17 | |
| Female | Male | 0.77 | 0.02 | 0.63 | 0.96 |
| Age 50–54 years | 55-59 | 1.49 | 0.00 | 1.15 | 1.93 |
| 60-64 | 3.03 | 0.00 | 2.23 | 4.10 | |
| 65-69 | 2.09 | 0.00 | 1.45 | 3.01 | |
| 70-74 | 3.09 | 0.00 | 1.93 | 4.92 | |
| WA | NSW | 0.81 | 0.20 | 0.59 | 1.12 |
| QLD | 1.19 | 0.30 | 0.86 | 1.65 | |
| SA | 1.41 | 0.04 | 1.02 | 1.96 | |
| VIC | 0.86 | 0.34 | 0.62 | 1.18 | |
| Self-Efficacy | N/A | 1.73 | 0.00 | 1.45 | 2.07 |
Distribution of individuals across decision stages at baseline
|
|
|
| |||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| Never Heard Of Screening | 141 | 105 | 88 | 334 | |
|
|
|
|
| ||
| Heard But Not Considered Screening | 195 | 198 | 227 | 620 | |
|
|
|
|
| ||
| Does not Want to Screen | 7 | 3 | 2 | 12 | |
|
|
|
|
| ||
| Unsure About Screening | 45 | 38 | 34 | 117 | |
|
|
|
|
| ||
| Wants to Screen | 392 | 372 | 380 | 1144 | |
|
|
|
|
| ||
| TOTAL | 780 | 716 | 731 | 2227 | |
|
|
Impact of intervention and psychological variables on FOBT return of participants (n = 1083) not yet ready to screen at baseline
|
|
| ||||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| Control | Non-Tailored | 1.91 | .001 | 1.276 | 2.621 |
| Tailored | 1.64 | .012 | 1.106 | 2.219 | |
| Salience & Coherence | N/A | 1.38 | .022 | 1.049 | 1.845 |
| Perceived Susceptibility | N/A | .67 | .006 | .498 | .891 |
| Self-Efficacy | N/A | 1.61 | .000 | 1.264 | 2.128 |
Descriptive statistics for baseline and endpoint psychosocial variables for each condition and FOBT return group
|
|
|
|
|
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 | T2 | T1 | T2 | ||
| Control |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| CI – Low | 4.30 | 4.30 | 2.72 | 2.70 | 2.75 | 2.69 | 3.68 | 3.72 | 3.97 | 4.05 | 2.32 | 2.14 | 3.41 | 3.51 | |
| CI – High | 4.38 | 4.39 | 2.88 | 2.86 | 2.83 | 2.77 | 3.77 | 3.81 | 4.06 | 4.15 | 2.45 | 2.27 | 3.53 | 3.63 | |
| Non-Tailored |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| CI – Low | 4.26 | 4.30 | 2.80 | 2.74 | 2.83 | 2.78 | 3.75 | 3.73 | 3.94 | 4.06 | 2.38 | 2.10 | 3.65 | 3.62 | |
| CI – High | 4.35 | 4.39 | 2.96 | 2.91 | 2.92 | 2.87 | 3.83 | 3.84 | 4.03 | 4.16 | 2.52 | 2.24 | 3.76 | 3.72 | |
| Tailored |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| CI – Low | 4.21 | 4.34 | 2.76 | 2.68 | 2.77 | 2.83 | 3.70 | 3.75 | 3.93 | 4.10 | 2.37 | 2.00 | 3.60 | 3.68 | |
| CI – High | 4.30 | 4.43 | 2.92 | 2.86 | 2.85 | 2.93 | 3.79 | 3.86 | 4.02 | 4.21 | 2.50 | 2.13 | 3.71 | 3.79 | |
| FOBT Non-Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| CI – Low | 4.13 | 4.08 | 2.66 | 2.81 | 2.71 | 2.71 | 3.66 | 3.62 | 3.77 | 3.42 | 2.43 | 2.43 | 3.35 | 3.43 | |
| CI – High | 4.32 | 4.26 | 2.99 | 3.15 | 2.88 | 2.88 | 3.82 | 3.82 | 3.97 | 3.68 | 2.71 | 2.73 | 3.59 | 3.64 | |
| FOBT Return |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| CI – Low | 4.28 | 4.35 | 2.79 | 2.72 | 2.80 | 2.78 | 3.72 | 3.76 | 3.98 | 4.15 | 2.37 | 2.07 | 3.58 | 3.63 | |
| CI – High | 4.33 | 4.40 | 2.89 | 2.82 | 2.85 | 2.84 | 3.78 | 3.82 | 4.03 | 4.20 | 2.45 | 2.15 | 3.65 | 3.70 | |